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ABSTRACT 
Functional Characterization of Acyl-CoA Binding Protein (ACBP) and Oxysterol Binding 
Protein-Related Proteins (ORPs) from Cryptosporidium parvum.  
 (December 2006) 
Bin Zeng, B.S., Jiangxi Agricultural University; 
M.S., China Agricultural University 
Chair of Advisory Committee: Dr. Guan Zhu 
 
From opportunistic protist Cryptosporidium parvum we identified and functionally assayed 
a fatty acyl-CoA-binding protein (ACBP) gene. The CpACBP1 gene encodes a protein of 
268 aa that is three times larger than typical ~10 KD ACBPs  of humans and animals. 
Sequence analysis indicated that the CpACBP1 protein consists of an N-terminal ACBP 
domain (approximately 90 aa) and a C-terminal ankyrin repeat sequence (approximately 
170 aa). The entire CpACBP1 open reading fragment (ORF) was engineered into a 
maltose-binding protein fusion system and expressed as a recombinant protein for 
functional analysis. Acyl-CoA-binding assays clearly revealed that the preferred binding 
substrate for CpACBP1 is palmitoyl-CoA. RT-PCR, Western blotting and immunolabelling 
analyses clearly showed that the CpACBP1 gene is mainly expressed during the 
intracellular developmental stages and that the level increases during parasite 
development. Immunofluorescence microscopy showed that CpACBP1 is associated with 
the parasitophorous vacuole membrane (PVM), which implies that this protein may be 
involved in lipid remodelling in the PVM, or in the transport of fatty acids across the 
membrane. 
 
 
 iv
We also identified two distinct oxysterol binding protein (OSBP)-related proteins (ORPs) 
from this parasite (CpORP1 and CpORP2). The short-type CpOPR1 contains only a 
ligand binding (LB) domain, while the long-type CpORP2 contains Pleckstrin homology 
(PH) and LB domains. Lipid-protein overlay assays using recombinant proteins revealed 
that CpORP1 and CpORP2 could specifically bind to phosphatidic acid (PA), various 
phosphatidylinositol phosphates (PIPs), and sulfatide, but not to other types of lipids with 
simple heads. Cholesterol was not a ligand for these two proteins. CpOPR1 was found 
mainly on the parasitophorous vacuole membrane (PVM), suggesting that CpORP1 is 
probably involved in the lipid transport across this unique membrane barrier between 
parasites and host intestinal lumen. Although Cryptosporidium has two ORPs, other 
apicomplexans, including Plasmodium, Toxoplasma, and Eimeria, possess only a single 
long-type ORP, suggesting that this family of proteins may play different roles among 
apicomplexans. 
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CHAPTER I 
 
INTRODUCTION 
 
Cryptosporidium is a genus of protozoan parasites belonging to the phylum 
Apicomplexa. At least 14 species within the genus have been reported from humans 
and a wide range of vertebrates including cattle, horses, dogs, cats and mice (Caccio, 
2005; Chen et al., 2002a; Thompson et al., 2005; Tzipori & Widmer, 2000b) 
 
Although Cryptosporidium typically causes only self-limited disease in 
immunocompetent patients, its infection in immunocompromised (such as AIDS 
patients) can be prolonged and life-threatening. Cryptosporidium parvum (zoonotic) and 
C. hominis (almost exclusively found in humans) are the two species commonly found 
in human patients, but a few other species have also been reported to infect humans, 
including C. meleagridis, C. felis, C. canis, C. suis and C. muris(Caccio, 2005; 
Thompson et al., 2005; Xiao & Ryan, 2004).  
 
Because the environmental stage, the oocyst, of Cryptosporidium spp. is highly 
resistant to all commonly used disinfectants including chlorine treatment, its 
contamination in a community water supply system can be a great threat to public 
health. Therefore, it is listed as a category B pathogen in the NIH Biodefense program. 
 
 
 
                                                                                
This dissertation follows the style of Microbiology. 
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Today, nitozaxanide (NTZ) is the only drug recently approved by the FDA to treat  
cryptosporidiosis in immunocompetent patients. However, this drug is not 100% 
effective against Cryptosporidium, and can be easily shadowed by the emerging drug 
resistance. Therefore, there is an urgent need to further understand the critical 
metabolism in this parasite to facilitate the discovery and development of new anti-
cryptosporidiosis compounds. 
 
The present project has been focusing on the two types of lipid binding proteins (acyl-
CoA binding protein [ACBP] and oxysterol-binding protein-related proteins [ORPs]) 
identified from the C. parvum genome. The aims of the study are to characterize the 
molecular and biochemical features of these parasite proteins as part of the lipid 
metabolic pathway, which may not only deepen our understanding on the basic 
biochemistry in C. parvum, but also provide the basis for exploring these proteins as 
potential therapeutic targets.  
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CHAPTER II 
 
REVIEW OF LITERATURE 
 
BACKGROUND 
 
The history of Cryptosporidium spp. 
 
In 1907, Ernest E. Tyzzer reported the first Cryptosporidium species, C. muris, that was 
isolated from a laboratory mouse (Tyzzer,1907). Tyzzer also reported the second 
species in this genus, C. parvum, that is zoonotic and commonly used as a model 
organism for studying cryptosporidiosis (Tyzzer, 1912). Fifty years later, the third 
species, C. meleagridis, was isolated from turkey, which was shown to be associated 
with the economic loss to the turkey industry.  Cryptosporidiosis infections in humans 
were reported in 1976.  Since the early 1980s, Cryptosporidium has been one of the 
important opportunistic pathogens among AIDS patients whose immune systems were 
comprised by HIV viruses. Since then, cryptosporidiosis-associated diarrhea was also 
reported among children in day care centers, and in other age groups whose immune 
systems were competent.  
 
In the past few years, over 10,000 people in more than 31 locations have been reported 
to have acquired Cryptosporidium infection from recreational waters (Fayer et al., 
2000). The noteworthy symptom associated with Cryptosporidium infection in humans 
is diarrhea, usually voluminous and watery (Fayer, 2004). C. parvum usually causes 
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self-limiting diarrhea in immunocompetent individuals. However, immunocompromised 
individuals can develop a life-threatening infection (Chen et al., 2002; Chappell and 
Okhuysen, 2002). There have been two genotypes of C. parvum: type I was only 
isolated from humans, while type II could infect both humans and animals. More 
recently, genotype I C. parvum has been pronounced by some investigators as a new 
species, C. hominis, based on biological and molecular data (Morgan-Ryan et al., 
2002).  
 
Life cycle and morphology of Cryptosporidium spp. 
 
Cryptosporidium belongs to the phylum Apicomplexa, in which all members are 
parasites. Many apicomplexans are important human and/or animal pathogens, such as 
those cause malaria (Plasmodium spp.), Texas Fever (Babesia spp.), toxoplasmosis 
(Toxoplasma gondii), and coccidiosis (Eimeria spp.) (Fayer et al., 2000). The life cycle 
of C. parvum resembles that of other coccidia, which consists of complex sexual and 
asexual stages (Fig. 2.1). It begins with the ingestion of infectious oocysts by humans 
or animals. Oocysts are an environmental stage with a highly chemical-resistant oocyst 
wall that contains 4 naked sporozoites. In the guts of humans or animals, the 
sporozoites emerge from oocysts by a process called excystation and invade the 
epithelial cells typically in the small intestine. Parasitophorous vacuoles (PV) form when 
the host cell plasma membrane engulfs and surrounds the invaded sporozoites. The 
sporozoites become trophozoites (“type I” meronts), and differentiate asexually into 8 
merozoites after the first generation of merogony. Mature merozoites will rupture host 
cells and invade into new cells to form “type II” meronts by a second generation of 
merogony. Four merozoites are typically formed in a “type II” meront. Type II 
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merozoites may differentiate into microgamonts or macrogamonts. A zygote forms 
when a macrogamete is fertilized by a microgamete. Zygotes will first develop into 
premature oocysts with the formation of the oocyst wall, and then into mature oocysts, 
each containing 4 fully developed sporozoites. The formation of sporozoites is termed 
as sporulation.  The sporulation of Cryptosporidium spp. takes place within the same 
host immediately after the formation of oocysts, whereas sporulation in typical coccidia 
(e.g., Eimeria or Cyclospora) takes place in the environment. There are two types of 
oocysts. The first type is thick-walled, while the other is thin-walled. There was an 
estimate that the ratio between thick- and thin-wall oocysts may be around 4:1 (Current 
& Garcia, 1991). Sporozoites in the thin-walled oocysts may excyst and infect the 
additional intestinal cells within the same host gut. Such a continuous recycling of 
infection is referred to as “auto-infection” or “auto-infective cycle”.  
 
 
Fig. 2.1. Life Cycle of Cryptosporidium parvum and C. hominis. (Reproduced 
from http://www.dpd.cdc.gov/dpdx/HTML/Cryptosporidiosis.html ) 
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In comparison to the oocysts of other intestinal coccidia, those of C. parvum are 
relatively small. The oocyst is subspherical, to most of the species in this genus. The 
typical size is 4.5–7.5 μm X 4.2–5.7 μm. The sizes of other life cycle stages are as 
follow:  sporozoites, 4.5–7.5 μm X 1.2–1.8 μm; meronts, spherical 4.0–6.9 μm diameter; 
merozoites, 3.6–5.0 μm × 1.1 μm; microgamont, ~1.7 μm long (Harris et al., 2003). 
 
Cryptosporidium parasitizes the surface of the host cell. However, they are intracellular 
parasites residing in the parasitophorous vacuoles (PV) covered by host cell 
membranes referred to as PV membranes (PVM) (Fig. 2.2). Since intracellular C. 
parvum does not reside within the host cell cytosol, it is referred to as an 
“extracytoplasmic” parasite (Zhu, 2004). Another unique structure is the “feeder  
 
 
Fig. 2.2. A diagram of the parasitophorous vacuole (PV). HM: host membrane; FO: 
feeder organelle, DB; DB: electron dense band (Mead, 2002). 
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organelle (FO)”, which is shown as a complex of folded membrane structure coupled 
with an electron-dense band at the parasite-host cell interface and contains a great 
amount of alpha-actin filaments at the host cell side (Beyer et al., 2002; Elliott & Clark, 
2000). Because of their specific locations, both the PVM and the “feeder organelle” are 
believed to play critical roles in the transport of nutrients from the intestinal lumen or 
host cells by the parasite. 
 
Cryptosporidiosis  
 
Both humans and animals acquire cryptosporidiosis by a fecal-oral transmission route 
(Egger et al., 1990). However, the source of oocysts can be water, food, or direct 
contact between human or animal individuals. There was a study showing that 2% of 
the stool samples collected from health care providers in the United States were 
Cryptosporidium positive  (Mead, 1999). In industrialized and developing countries, the 
prevalence for Cryptosporidium in human stools ranges from 2.1 to 6.1%  (Martins & 
Guerrant, 1995). Several major waterborne outbreaks of cryptosporidiosis have been 
reported. The largest waterborne outbreak occurred in Milwaukee, Wisconsin, USA in 
1993, which infected about 403,000 people and caused more than 100 deaths among 
immunocompromised individuals (MacKenzie et al., 1995; Soave, 1995). The 
epidemiology of the Cryptosporidium infection has the following characteristics  (Caccio 
& Pozio, 2006): 1) low infective dose; 2) immediate infectivity of excreted oocysts; 3) 
very high stability of oocysts (one month to more than 1 year when exposed to 
environment); 4) easy dispersal in environmental contamination (drinking water and 
food); and 5) great zoonotic potential. 
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Cryptosporidium can cause immunocompetent individuals self-limited diarrhea, which 
generally produce mild to severe diarrhea that may last for days or up to 2–3 weeks. 
The clinical signs manifest as a cholera-like diarrhea, vomiting nausea, abdominal pain, 
loss of appetite, fatigue, and weight loss. Among immunocompromised individuals, 
such as AIDS patients, cryptosporidiosis is chronic and life-threatening. During an 
outbreak in Nevada, the median weight loss of HIV-positive patients was 29.9 lb and 
the median duration of diarrhea was ~60 days  (Goldstein et al., 1996). Forty of the 61 
AIDS patients infected with Cryptosporidium in this outbreak died within 6 months. 
Cryptosporidium in HIV-positive patients may also disseminate from the small intestine 
to other atypical places, such as the gall bladder, biliary tract, pancreas, or even 
respiratory system  (Lopez-Velez et al., 1995). For example, in the Milwaukee outbreak, 
Among 81 patients were diagnosed as cryptosporidiosis, 25% of them were found to 
have Cryptosporidium infection in their extraintestinal biliary tracts. 
 
Today, there are still no completely effective drugs to treat cryptosporidiosis. 
Nitazoxanide (NTZ) is the only drug recently approved by FDA to treat cryptosporidiosis 
in immunocompetent patients (but not in immunocompromised individuals) in the United 
States. Paromomycin is another compound frequently mentioned in the literature, but in 
a recent clinic trial, it was found to be no more effective than placebo for treating 
cryptosporidiosis in patients with advanced HIV infection  (Hewitt et al., 2000). 
However, due to its efficacy against Cryptosporidium infection in vitro, paromomycin is 
commonly used as a standard positive control in drug studies  (Mead, 2002; Meamar et 
al., 2006; Rossignol, 2006). 
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Fatty acid metabolism in Cryptosporidium 
 
Fatty acids are one of the major components of biomembranes. Despite of its 
importance, fatty acid metabolism in Cryptosporidium and other apicomplexans is a 
relative new area of research, only starting with the discovery of type II fatty acid 
synthases (FASs) in Plasmodium falciparum and Toxoplasma gondii (Waller et al., 
1998), and that of type I FAS in Cryptosporidium (CpFAS1) (Zhu et al., 2000c). In type I 
system, all major enzymes involved in fatty acid synthesis are fused into one or two 
polypeptides, whereas in the type II system, all enzymes are discrete and 
monofunctional proteins. More recently, the apicomplexan genome projects have 
revealed that a type FAS is also present in T. gondii, but not in Plasmodium spp. (Zhu, 
2004). In addition, a type I polyketide synthase (PKS) is also identified from the 
genomes of C. parvum and T. gondii, suggesting these parasites are capable of making 
more sophisticated fatty acid derivatives (Zhu et al., 2002; Zhu et al., 2004).  
 
Besides type I FAS and PKS, C. parvum also possesses a long chain fatty acid 
elongase and its associated pathway for elongating long chain fatty acyl-CoAs. 
Because of the lack of type II FAS that is responsible for de novo synthesis of fatty 
acids (Zhu et al., 2000b), together with the fact that CpFAS1 prefers the long chain fatty 
acids as its substrates (Zhu et al., 2004), C. parvum appears to be incapable of 
synthesize fatty acids de novo, and has to scavenge fatty acids from host cells or the 
intestinal lumen. 
 
In addition to the fatty acid synthetic enzymes, several lipid binding proteins are also 
present in the C. parvum genome, which include an ankyrin-containing acyl-CoA 
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binding protein (ACBP) and two oxysterol-binding protein-related proteins (ORPs). 
These lipid binding proteins are typically involved in the storage and transport of lipids 
(Im et al., 2005; Knudsen et al., 1993; Knudsen et al., 1999; Lehto & Olkkonen, 2003; 
Rasmussen et al., 1994). However, their roles in regulating lipid and sterol metabolism 
are also well documented (Choi et al., 1996; Im et al., 2005; Kerkhoff et al., 1997; 
Knudsen et al., 1999; Knudsen et al., 2000; Olkkonen, 2004). The major players in the 
fatty acid metabolism in C. parvum, as well as their proposed roles are summarized by 
Zhu (Zhu et al., 2004).  
 
Fatty acid metabolism has served as a good drug target in bacteria. For example, enoyl 
reductase (ENR) has been identified as the true target both for diazaborines, including 
the front-line antituberculosis drug isoniazid (Baldock et al., 1998; Mdluli et al., 1998), 
and for triclosan and other 2-hydroxydipheyl ethers (Heath et al., 1998; Heath et al., 
1999; McMurry et al., 1999). This pathway is also being explored as rational drug target 
in apicomplexans. For example, thiolactomycin and triclosan have been found to 
potently inhibit the growth of P. falciparum in vitro and P. berghei in vivo (a mouse 
model) (Surolia & Surolia, 2001). Cerulenin, a metabolite of Cephalosporium caerulens, 
is a specific inhibitor to both types I and II β-keto-acyl-[ACP] synthases (Heath et al., 
2001; Mead, 2002). This compound has been shown to inhibit the growth of C. parvum 
in vitro without apparent toxicity to the host cells, indicating that fatty acid metabolism 
may also serve as a rational drug target in Cryptosporidium  (Zhu et al., 2000b; Zhu 
2004). 
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Acyl-CoA Binding Protein (ACBP) 
 
Acyl-CoA binding protein (ACBP) was named after the protein’s high ability to bind to 
medium to long chain acyl-CoA esters. ACBP was first isolated from bovine liver 
(Mikkelsen & Knudsen, 1987). It was also found that ACBP and diazepam-binding 
inhibitor (DBI) were the same protein (Knudsen, 1991), which could displace diazepam 
from the benzodiazepine recognition site of the gamma-aminobutyric acid receptor 
(Guidotti et al., 1983; Kragelund et al., 1999). ACBP homologues are present in almost 
all eukaryotes, including animals, plants, fungi and protists. ABCPs are typically short, 
~10 kDa proteins. However, longer versions of ACBPs fused with other types of 
domains (e.g., ankyrin repeats) are also present. For example, Arabidopsis thaliana has 
at least 3 long type ACBPs, in which AtACBP2 contains an N-terminal ankyrin repeats 
probably responsible for interacting with other proteins (Li & Chye, 2004). 
 
Although ACBPs can bind to a wide range of fatty acyl CoA esters, each ACBP may 
have different binding profile towards various fatty acyl chain lengths. For example, 
bovine intestinal ACBP (bACBP) prefers to long chain fatty acyl-CoAs (LCFA, C14 - 
C20), whereas Trypanosoma brucei ACBP (TbACBP) apparently has higher affinity 
towards medium chain acyl-CoAs (MCFA, C10 - C14) (Milne & Ferguson, 2000). On the 
other hand, P. falciparum ACBP (PfACBP) appears to have relatively similar binding 
affinity towards all medium to long chain acyl-CoAs (C14 – C22) (van Aalten et al., 
2001).  
 
ACBPs may function as acyl-CoA transporters. In the parasite T. brucei, ACBP was 
found to be responsible for transport or delivery of the fatty acyl chains for synthesizing 
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the GPI anchors (Milne & Ferguson, 2000). ACBPs are also involved in the regulation 
and forming of the intracellular acyl-CoA pool. For example, overexpression of S. 
cerevisiae ACBP has increased the intracellular acyl-CoA pool size in the yeast 
(Knudsen et al., 1994). In another experiment, transgenic mice expressing a higher 
level ACBP was studied. Although the transgenic mice didn’t show the change to their 
body and liver weights, the pool size of liver LCFA-CoA was expanded by 69%, 
especially to the saturated and polyunsaturated, but not monounsaturated, LCFA-CoAs 
(Huang et al., 2005). On the other hand, the liver acyl-CoA pool was significantly 
reduced in ACBP gene knockout mice (Martin et al., 2003).  
 
Cells may utilize the ACBP-associated acyl-CoA pools as one of the means in 
regulating fatty acid metabolism. For example, in human mononuclear phagocytes, the 
activity of acyl-CoA:cholesterol acyltransferase (ACAT) in rough endoplasmatic 
reticulum membranes could be inhibited by a molar ratio of ACBP/oleoyl-CoA in its 
complexes (Kerkhoff et al., 1997). However, ACAT activity was not affected by other 
lipid binding proteins such as bovine serum albumin (BSA) and the liver fatty acid 
binding protein (FABP). 
 
Oxysterol Binding Protein-Related Protein (ORP) 
 
Oxysterol-binding protein (OSBP) was first identified in humans by its ability to bind to 
oxysterols, 27-carbon products of cholesterol oxidation (Kandutsch et al., 1977; 
Kandutsch & Shown, 1981). OSBPs were found to inhibit the cholesterol biosynthesis 
by repressing the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which 
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indicates that OSBP plays a role in the regulation of cholesterol homeostasis (Lehto & 
Olkkonen, 2003; Taylor et al., 1984; Taylor & Kandutsch, 1985). Since then, numerous 
OSBP homologues were identified from humans, animals, fungi and many other 
organisms. Because not all OSBP homologues may bind to oxysterols, this group of 
proteins was then renamed to OSBP-related proteins (ORPs). It is currently known that 
all ORPs can bind to various types of phosphatidyl-inositol phosphates (PIPs) with 
different binding profiles (Lehto & Olkkonen, 2003; Olkkonen, 2004; Olkkonen et al., 
2006). The recently completed genome-sequencing projects have revealed at least 11 
ORP homologues in humans and 7 in the budding yeast. Some of them are long type 
ORPs containing both pleckstrin homology (PH) and ligand binding (LB) domains, while 
others are short, only containing the LB domain (Im et al., 2005; Lehto & Olkkonen, 
2003). Although there has been an increasing interest to use yeast model to study 
ORPs, the ligand-binding features and biological roles of all yeast ORPs are not fully 
understood yet. Knockout of any single ORP gene is not lethal in yeast, but changes 
the sterol profile. However, yeast apparently cannot survive when all 7 ORP genes are 
knocked out, which suggesting some overlapping functions among these homologues 
(Beh & Rine, 2004; Lehto & Olkkonen, 2003; Lessmann et al., 2006). 
While all ORPs have the ligand binding (LB) domain, some of them may contain a 
pleckstrin homology (PH) domain. The human OSBP (hOSBP) contains both PH and 
LB domains. Upon binding to the ligand (i.e., 25-hydroxycholesterol [25-OHC]), hOSBP 
will be translocated to the Golgi apparatus, which facilitates the transport of oxysterols 
to the Golgi. PH domain appears to be responsible for the binding of hOSBP to the 
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Golgi, as the mutated, LB-lacking OSBP was still able to bind to this organelle in 
transfected cells (Ridgway et al., 1992). The ability for PH domain to bind to various 
PIPs was reported in ORPs and other PH domain-containing proteins, such as the 
phospholipase C-δ1. In the later case, the PH domain displays high affinity to 
PtdIns(4,5)P2. On the other hand, the short-type ORPs were also shown to be able to 
bind to PIPs, suggesting that the PH domain is not the sole region responsible for the 
PIP-binding in ORPs (Beh & Rine, 2004). 
 
The research data presented in this dissertation focuses on the molecular and 
biochemical characterizations of an ACBP and two ORPs in C. parvum as part of the 
fatty acid metabolism project running in the laboratory. Genes encoding the three lipid-
binding proteins were cloned, sequenced and engineered into a maltose-binding protein 
(MBP)-fusion system. Recombinant proteins were expressed in bacteria and their 
biochemical features, including binding specificity and kinetics, were analyzed in detail. 
Specific polyclonal antibodies were also generated for protein detections by western 
blot analysis and immunofluorescence microscopy. Our results revealed that these lipid 
binding proteins differ from the counterparts in mammals, and two of them are localized 
in the unique PVM, suggesting that they are probably involved in the lipid uptake 
across, and/or the participation of membrane regeneration of the PVM by the parasite. 
(Chen et al., 2002a) 
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CHAPTER III 
 
CHARACTERIZATION OF A FATTY ACYL-CoA BINDING PROTEIN (ACBP) 
FROM THE APICOMPLEXAN CRYPTOSPORIDIUM PARVUM* 
 
INTRODUCTION 
 
Cryptosporidium parvum is a globally important parasitic protist that infects both 
humans and animals (Chappell & Okhuysen, 2002; Thompson et al., 2005; Tzipori & 
Widmer, 2000a). Cryptosporidium parvum belongs to the Phylum Apicomplexa that 
contains many important human and animal parasites (e.g. Plasmodium, Babesia, 
Toxoplasma and Eimeria) (Zhu et al., 2000a). This group of parasites shares some 
common biological features characteristic to the phylum. For example, all 
apicomplexans possess similar complex life cycle stages including oocyst formation, 
sporulation, merogony and gametogenesis. However, recent advancements in 
biochemistry and  genome-sequencing have revealed that a number of metabolic 
pathways such as fatty acid biosynthesis are highly diverse within the Apicomplexa 
(Abrahamsen et al., 2004; Zhu et al., 2000a). Apicomplexans may possess either 
apicoplast-specific Type II fatty acid synthases (FASs) (e.g.,  P. falciparum), or Type I 
FAS (e.g., C. parvum), or both (e.g., T. gondii) (Roos et al., 2002; Zhu, 2004b) (Zhu et 
al., 2000e; Zhu et al., 2002; Zhu et al., 2004b). Although fatty acids are one of the major 
components in all cells, free fatty acids cannot enter any metabolic pathways unless  
 
 
 
 
*Reprinted with permission from “Functional characterization of a fatty acyl-CoA-
binding protein (ACBP) from the apicomplexan Cryptosporidium parvum” by Zeng 
B., Cai X & Zhu G., 2006. Microbiol 152, 2355-63. Copyright 2006 by the Society for 
General Microbiology.                          
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they are activated by thioesterification with coenzyme A (CoA) to form an acyl-CoA or                                 
with acyl carrier protein (ACP) to form an acyl-ACP. Fatty acyl-CoA can immediately 
enter subsequent metabolic pathways, or may be stored/transported by a family of acyl-
CoA binding proteins (ACBPs). 
 
ACBPs are a group of highly conserved proteins and have been found in animals, 
plants, protists, and a number of pathogenic bacteria (Burton et al., 2005). They are 
typically small, cytosolic molecules of ~10 kDa. However, a number of larger ACBP 
proteins (e.g. Mr >55-kDa) have also been identified in both animals and plants. 
Mammals possess multiple ACBP proteins that are differentially expressed in various 
tissues (e.g. T-ACBP in testis, L-ACBP in livers and I-ACBP in intestines) (Schroeder et 
al., 1998). In Trypanosoma brucei, an ACBP protein was found to be involved in the 
synthesis of the glycosyl-phosphatidylinositol (GPI) anchor in variant surface 
glycoproteins (VSG) (Milne & Ferguson, 2000; Milne et al., 2001). Although ACBPs are 
capable of binding medium to long chain fatty acyl-CoA esters, they may vary in their 
substrate preference and binding affinities. For example, the highest affinities of ACBP 
proteins from bovine (liver) and trypanosome (or P. falciparum) are C18 stearoyl- and 
C14 lauroyl-CoA, respectively (Milne & Ferguson, 2000; van Aalten et al., 2001). 
 
By data-mining the recently completed C. parvum genome sequences, we have 
identified a unique long-type ACBP (CpACBP1) that contains an N-terminal ACBP 
domain and a C-terminal ankyrin-repeat sequence, which is structurally similar to the 
membrane-associated ACBP1 and ACBP2 in Arabidopsis thaliana. In the present study, 
we have expressed CpACBP1 protein as a fusion protein and characterized its primary 
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biochemical features. We have also found that the CpACBP1 gene is differentially 
expressed during the parasite life cycle, and its encoded protein is chiefly located on 
the parasitophorous vacuole membranes (PVM), suggesting that this protein may be 
involved in the formation of PVM and/or uptake of fatty acids by the parasite. 
 
METHODS 
 
Manipulation of parasite 
 
Oocysts of C. parvum (Iowa strain) were purchased from Grass Bunch Farm (Deary, 
ID). The limited amount of bacterial contaminants and debris were removed with a 
Percoll gradient centrifugation technique and sterilized for 5 min in 10% Clorox® on ice. 
After washing in sterile water 5-8 times, the sterilized oocysts were excysted for 1-1.5 hr 
at 37˚C in phosphate buffered saline (PBS, pH 7.5) containing 0.25% trypsin and 0.75% 
taurodeoxycholic acid. Sporozoites were washed 3-5 times with sterile water and 
concentrated as previously described (Millership & Zhu, 2002; Zhu et al., 2000d). 
Genomic DNA (gDNA) was isolated from the free sporozoites using the DNeasy 
isolation kit (Qiagen, Valencia, CA). 
 
Identification of ACBP homologues from C. parvum and other apicomplexans 
 
CpACBP1 was identified from the C. parvum genome as an intronless gene by a 
homology-search using characterized animal and plant ACBP proteins as queries. 
Similar searches were also performed to identify ACBP homologues from the 
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Plasmodium falciparum and Toxoplasma gondii genome databases 
(http://www.PlasmoDB.org and http://www.ToxoDB.org, respectively) for comparison. 
Domains in the apicomplexan ACBP homologues were identified by searching the 
Conserved Domain Database at the National Center for Biotechnology Information 
(NCBI, http://www.ncbi.nlm.nih.gov) and by comparing with other characterized proteins 
in the GenBank database. 
 
Molecular cloning and engineering of CpACBP1 
 
To facilitate biochemical analysis, we cloned CpACBP1 and expressed CpACBP1 as a 
maltose-binding protein (MBP)-fusion as described below. Briefly, the entire open reading 
frame (ORF) of CpACBP1 was amplified from C. parvum (Iowa strain) genomic DNA 
(gDNA) with the following pair of primers:  5’-ATG ACT GAT ATC TTA TCC ACG AAC-3’ 
and 5’-atg gat ccT TAA CTG CTT TCG AGA ATT CTT-3’ (Note: lower cases represent 
added BamHI restriction site). A high-fidelity Pfu DNA polymerase (Stratagene) was used 
to minimize potential errors introduced by amplification. The PCR product was digested 
with BamHI to produce a cohesive 3’ end, but retained the blunt 5’ end to facilitate 
unidirectional cloning. The 5’ ends were phosphorylated by treating the amplicons with T4 
polynucleotide kinase. After agarose gel electrophoresis, DNA fragments of the expected 
size were purified using a MinElute gel extraction kit (Qiagen), and ligated into an XmnI 
and BamHI double-digested pMAL-c2x vector (New England Biolabs) with a T4 DNA 
ligase. The ligated plasmids were transformed into the TOPO-10 strain of Escherichia coli 
cells (Invitrogen). The resulting colonies were first screened using a sense-stranded 
primer located upstream to the insert in the vector and the CpACBP1 antisense-stranded 
primer. Plasmids were isolated from PCR-positive colonies for sequencing to confirm their 
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identity and the sequence of the inserts. The resulting construct and encoded fusion 
protein were named pMAL-c2x-CpACBP1 and MBP-CpACBP1, respectively. 
 
Similarly, we also constructed an MBP-fusion containing only the ACBP domain. Because 
of the presence of two EcoRI restriction sites flanking the ankyrin domain (i.e., 
nucleotides from 298 to 788), we removed the entire C-terminal ankyrin repeats by 
digesting pMAL-c2x-CpACBP1 plasmid with EcoRI and agarose gel separation. The 
remaining plasmid fragment was re-ligated back, resulting a construct (pMAL-c2x-
CpACBP1-S) that encodes only the N-terminal 100 amino acids (aa) plus 7 extra aa 
derived from the remaining nucleotides at the 3’ end of insert and the vector’s multiple 
cloning site (MBP-CpACBP1-S). We predict that the extra 7 aa (RKQLRIL) will not alter 
the function of the ACBP domain as they do not resemble any known functional 
sequences in the databases. 
 
For each construct, a plasmid containing the correct insert was transformed into E. coli 
Rosetta cells (Novagen) for protein expression. Briefly, a single clone of the E. coli 
transformants was inoculated in 10 ml LB broth containing 100 mg ml-1 ampicillin and 34 
mg ml-1 chloramphenicol for growing overnight at 37 °C. On the second day, the bacterial 
suspension was transferred into 1 L fresh medium containing the two antibiotics and 
grown at 30 °C until the OD495 reached to 0.3-0.5. After adding IPTG to the broth (100 mg 
ml-1 final concentration), bacteria were further incubated for 4 hours at 30 °C and 
collected by centrifugation for 10 min at 8,000 g. Bacterial pellets were suspended in 50 
ml of column buffer (20 mM Tris-HCl, pH 7.5, 20 mM NaCl, 2 mM EDTA) containing a 
protease inhibitor cocktail for bacteria (Sigma-Aldrich), disrupted by sonication, and 
centrifuged (8,000 g, 10 min) to remove cell debris. Supernatants were applied to an 
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amylose-resin column (New England Biolabs), washed with column buffer (>10 X bed 
vol.), and the MBP-CpACBP1 fusion proteins were eluted from the column with elution 
buffer (10 mM maltose, 20 mM Tris-HCl, pH 7.5, 20 mM NaCl, 2 mM EDTA) according to 
the manufacturer’s protocol. The size and purity of the recombinant proteins were 
analyzed by SDS-PAGE. Protein concentrations were determined by the Bradford 
method using a commercial kit and bovine serum albumin (BSA) as standard. The 
aliquots of each protein sample were either used immediately or stored at -80 °C. 
 
Semi-quantitative RT-PCR 
 
The entire semi-quantitative RT-PCR (semi-qRT-PCR) procedure, including the isolation 
of parasite total RNA from various intracellular stages including asexual and sexual life 
cycles, the normalization of parasite RNA contents in intracellular samples, reverse 
transcription, amplification and analysis, has been previously described in detail 
(Millership et al., 2004a; Millership et al., 2004b). In this study, the following pair of 
primers was used to amplify CpACBP1 transcripts: CpACBP1-F334 (5’-CCT TTA TTA 
GAA TCA AAC CTG G-3’) and CpACBP1-R334 (5’-TTG GAT AGG AGT CAA ACC ATC-
3’). Another pair of previously reported primers (995F, 5’-TAG AGA TTG GAG GTT GTT 
CCT-3’ and 1206R, 5’-CTC CAC CAA CTA AGA ACG GCC-3’) was used to amplify 18S 
rRNA as a control for normalization (Abrahamsen & Schroeder, 1999). Each semi-qRT-
PCR reaction contained a comparable amount of parasite RNA, and was subjected to 45-
min reverse transcription and 23 (for CpACBP1) or 20 (for 18S rRNA) thermal cycles of 
PCR amplification. After agarose gel electrophoresis, the intensity of each product was 
measured using GENETOOLS program v.3 (Hitachi Software Engineering) and the 
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relative level of CpACBP1 transcripts was determined as the signal ratio between the 
CpACBP1 and rRNA amplicons. 
 
Production of polyclonal antibodies to CpACBP 
 
Polyclonal antibodies to recombinant CpACBP1 protein were raised in a pathogen-free 
rabbit. Initial immunization used 0.2 mg of affinity-purified MBP-CpACBP1 protein 
emulsified in an equal 2 ml of complete Freund’s adjuvant. Two subsequent booster 
immunizations (0.1 mg) were injected on 30 and 60 days, after the primary immunization. 
Rabbit sera were collected prior to and after the immunization protocol. The anti-MBP 
portion of the polyclonal antibodies was removed by absorbing antiserum with equal 
volume of amylose-resin conjugated with MBP. The antibody titer and specificity were 
evaluated by western blot analysis.
 
Western blot analysis 
 
Western blot analysis was performed to test whether CpACBP1 protein is present in 
various parasite life cycle stages. Oocysts (5x106/lane), free sporozoites (2x107/lane), 
and HCT-8 cells (1x106/lane) infected with C. parvum oocysts (oocysts : host cell ratio = 
1:1) for 24, 48 and 72 hr were lysed in loading buffer containing a protease inhibitor 
cocktail for mammalian cells (Sigma-Aldrich) at 95 °C for 8 min. Uninfected HCT-8 cells 
cultured for the same periods of time were also lysed and used as controls. After 
centrifugation for 5 min, soluble materials were fractionated in a 10% SDS-PAGE gel 
and transferred onto a nitrocellulose membrane. The membrane was first blocked with 
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5% BSA in TBS (20 mM Tris pH 7.5, 50 mM NaCl) for 1 h, and then incubated with 
rabbit anti-CpACBP antibodies and a monoclonal anti-rabbit IgG antibody conjugated to 
alkaline phosphatase (Sigma-Aldrich) in 1% BSA in TBST (TBS with 0.05% Tween-20). 
The blot was washed 3 times with TBST after each incubation step, and all procedures 
were performed at room temperature. Finally, the labeled proteins were developed 
using 5’bromo-4-chloro-3-indolyl phosphate (BCIP) (Sigma-Aldrich). 
 
Immunofluorescence microscopy 
 
Intracellular parasites were prepared by infecting HCT-8 cells grown on poly-L-lysine-
treated glass coverslips for 24, 48 or 72 hr. Cells were fixed with 10% formalin, rinsed 
with PBS, extracted with cold methanol (-20 °C for 5 min), blocked in 0.5 % BSA-PBS 
(10 min), labeled with primary antibodies (1 hr in 0.5 % BSA-PBS), and incubated with 
secondary antibodies conjugated with FITC or TRITC (Sigma-Aldrich,  1/20 and 1/400 
dilution respectively)  (60 min in 0.5 % BSA-PBS). Samples were washed after each 
incubation step (3 times, 5 min each) using PBS. Free sporozoites were fixed in 
suspension, directly applied onto poly-L-lysine-treated coverslips, extracted, and air-
dried prior to the incubations with antibodies. Co-localization of CpACBP1 with total 
membrane proteins (TMP) and an SFP-type phosphopantetheinyl transferase (CpSFP-
PPT) immunolocalization was similarly performed, except that the respective rabbit 
antibodies were directly labeled with Alexa Fluor 488 or Alexa Fluor 546 using the 
appropriate fluorophore-labeling kits (Invitrogen) prior to the immuno-labeling 
experiments. No secondary antibodies were used in co-localization experiments. The 
TMP antibody has previously been shown to mainly label the PVM and feeder organ in 
intracellular parasites (Chen et al., 2003), while cytosolic localization of CpSFP-PPT 
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has also been previously reported (Cai et al., 2005). All samples were mounted using a 
SlowFade Light Antifade medium containing 4’, 6’-diamidino-2-phenylindole (DAPI) for 
DNA counter-staining (Invitrogen) and examined with an Olympus BX51 Epi-
Fluorescence microscope equipped with Differential Interference Contrast (DIC) and 
FITC/TRITC/DAPI filters.
 
Acyl-CoA binding assay 
 
The binding affinity of CpACBP1 with fatty acyl-CoA was measured by Lipidex 1000 
assay as previously described (Rasmussen et al., 1990; Rosendal et al., 1993). Briefly, 
40 pmol of recombinant CpACBP1 was mixed with [14C] palmitoyl-CoA (0 – 8 mM) in 100 
ml of binding buffer (10 mM potassium phosphate, pH 7.4) and incubated at 37 °C for 30 
min. The mixture was then chilled on ice for 10 min, mixed with 0.6 ml of cold Lipidex 
1000 (hydroxyalkoxypropyl dextran, Type VI from Sigma-Aldrich) (50% slurry, v/v in 
binding buffer) with gentle rotation at 4 °C for 1 hr, and centrifuged for 5 min at 12,000 g 
at 4 °C to remove free acyl-CoA esters. An aliquot of 200 ml supernatant was taken from 
each sample for counting radioactivity in a Beckman LS6500 scintillation counter. Each 
experiment included negative controls using MBP-tag only for background subtraction. At 
least three replicates were performed for each experimental condition. The dissociation 
constant (Kd) was determined by plotting the amount of bound substrate against the total 
concentration of substrate using nonlinear regression and Prism v4.0 (GraphPad 
Software).  
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The substrate preference for CpACBP1 was determined by a competition-binding 
assay. It was performed in 100 ml of binding buffer containing 40 pmol of recombinant 
CpACBP1 (or MBP in control groups) and 80 pmol of [14C] palmitoyl-CoA in the 
absence or presence of 80 pmol of non-radioactive fatty acyl-CoA esters of various 
chain lengths (i.e., ranging from 4 to 20 carbons). All samples were incubated, 
extracted with Lipidex 1000, and counted for radioactivity as described above. 
 
In addition, we also tested whether CpACBP1 could specifically bind to long chain fatty 
acid. In this assay, 80 pmol recombinant CpACBP1 protein was incubated with 80 pmol 
[3H] palmitic acid or [14C] palmitoyl-CoA in 100 ml buffer. After extraction with Lipidex 
1000, the supernatants were counted for radioactivity as described above. 
 
Autoradiography 
 
To visualize the binding of CpACBP1 with acyl-CoA, 80 pmol of fusion protein was 
incubated with 80 pmol of [14C] palmitoyl-CoA in the presence or absence of 80 pmol of 
non-radioactive palmitoyl-CoA in 100 ml of binding buffer for 30 min at 37 °C.  
Subsequently, 20 ml of the reaction was mixed with 5 ml of 5X native loading buffer, 
and fractionated in a 10% native PAGE gel. The gel was dried on a heated gel-drier and 
radioactive protein bands were visualized with X-ray film in a BioMax TranScreen LE 
intensifying system (Kodak). 
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RESULTS 
 
CpACBP1 is a “long-type” ACBP containing ankyrin repeats 
 
CpACBP1 (nucleotide sequence data are available in the GenBank database under the 
accession number DQ406676) is the only ABCP homologue that can be identified from 
the C. parvum genome by repeated BLAST searches using several animal, plant and 
protist ABCP proteins as queries. This intronless gene encodes 268 aa that constitute 
an N-terminal ACBP domain (~ 90 aa) and a C-terminal sequence (~178 aa) containing 
two ankyrin repeats (Fig. 3.1). Other apicomplexans appear to possess more ACBP 
homologues in their genomes. For example, P. falciparum has 4 ACBP homologues 
(PfACBPs, 3 short and one long), and T. gondii has two (TgACBPs, one short and one 
long). The small ACBP domains in all apicomplexan proteins share many conserved 
residues with their homologues found in animals and plants that are characteristic to 
this group of proteins (Fig. 3.2). Amino acids that are critical to the ligand binding 
activity are all present in CpACBP1 and other apicomplexan ACBPs (Fig. 3.2, indicated 
by solid dots) (Burton et al., 2005). Similar to CpACBP1, the long-type ACBP in T. 
gondii contains two ankyrin repeats (Fig. 3.1). However, it also possesses an N-terminal 
signal peptide, possibly for secretion. On the other hand, the P. falciparum long-type 
ACBP contains no ankyrin repeats (Fig. 3.1). These observations indicate that 
apicomplexans may differ from each other by possessing different numbers and types 
of ACBP proteins.  
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CpACBP1 has a highest binding affinity to C16:0 palmitoyl-CoA 
 
In order to investigate the binding features of CpACBP1, we have expressed the full-
length protein as well as the ACBP domain as MBP-fusion proteins (i.e., MBP- 
 
 
 
 
 
Fig. 3.1. Domain organization of CpACBP1 in comparison with those from other 
representative eukaryotic acyl-CoA binding proteins (ACBPs). Pf = Plasmodium 
falciparum. Tg = Toxoplasma gondii. At = Arabidopsis thaliana. Hs = Homo sapiens. 
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Fig. 3.2. Multiple alignment of conserved region in the ACBP domain between 
CpACBP1 and other representative eukaryotic ACBP proteins. Amino acids shared 
between CpACBP1 and other sequences are shaded, while residues conserved among 
all listed sequences are boxed. Pf = Plasmodium falciparum. Tg = Toxoplasma gondii. 
At = Arabidopsis thaliana. Hs = Homo sapiens. Numbers following the species 
abbreviations are the accession numbers in GenBank or the corresponding 
apicomplexan genome databases (http://www.PlasmoDB.org or 
http://www.ToxoDB.org). Solid dots indicate amino acids critical to the acyl-CoA binding 
activity.
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CpACBP1 and MBP-CpACBP1-S). Both fusion proteins were purified to homogeneity 
using amylose resin-based affinity chromatography (Fig. 3.3). Although the fusion 
proteins expressed using pMAL-c2x vector contain a factor Xa cleavage site, attempts 
to effectively remove the MBP-tag using factor Xa were not successful. It is possible 
that the MBP-CpACBP1 fusion protein folded in a way that interfered with the access of 
factor Xa to the cleavage site. The difficult in removing the MBP-tag was also observed 
for the recombinant C. parvum malate and lactate dehydrogenases, in which their 
activities were assayed with the presence of MBP-tag (Madern et al., 2004). 
 
Using the Lipidex 1000 assay, we first confirmed that the intact MBP-CpACBP1 was 
able to specifically bind to palmitoyl-CoA, while MBP had no or little affinity to the same 
ligand (Fig. 3.4A). With both ligand and protein concentrations at 80 mM (near the 
highest concentration of 100 mM in the kinetics assay), the nonspecific binding by 
MBP-tag was ~ 5% of the specific binding observed for MBP-CpACBP1. In another 
assay using both palmitic acid and palmitoyl-CoA as substrates, both MBP-tag and 
MBP-CpACBP1 displayed almost the same radioactivity in binding to the palmitic acid 
(Fig. 3.4B), indicating that fatty acid is not a favorite ligand for CpACBP1. Based on 
these observations, we decided to use the uncleaved fusion proteins in all subsequent 
analyses. 
 
We first studied the specific binding between CpACBP1 and palmitoyl-CoA and 
determined that the Kd for CpACBP1 to bind to palmitoyl-CoA was at 407 nM (Fig. 3.5). 
This value is significantly higher than those reported for many other ACBPs that are 
typically at 1 – 10 nM ranges (Burton et al., 2005). This observation suggests that, 
although Lipidex assay is a reliable assay for determining the acyl-CoA binding profile  
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Fig. 3.3.   SDS-PAGE analysis of purified MBP-fused CpACBP1 proteins. Short = MBP-
fusion protein containing ACBP domain only. Long = MBP-fusion protein containing the 
entire CpACBP1 sequence. M = protein molecular marker. 
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Fig. 3.4A. Specific and nonspecific binding of [14C] palmitoyl-CoA (80 mM) by MBP-
fused CpACP1 (40 mM) and MBP-tag (40 mM) by the Lipidex 1000 extraction assay.  
 
 
 
Fig. 3.4B. Relative binding between CpACBP1 and [14C] palmitoyl-CoA (80 mM) or [3H] 
palmitic acid as determined by Lipidex 1000 assay. Radioactivity was normalized using 
MBP-tag as control. 
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Fig. 3.5. Binding kinetics of recombinant CpACBP1 with palmitoyl-CoA as determined 
by Lipidex 1000 assay. 
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for an ACBP, it is probably not a sensitive method for determining the binding kinetics 
due to the binding competition between ACBP and Lipidex 1000 during the extraction 
step (Rasmussen et al., 1994). It is also possible that a significant portion of the 
CpACBP1 fusion protein was inactive and incapable of binding to acyl-CoA, and/or the 
N-terminal 42-kDa MBP-tag might physically interfere the binding kinetics of the 
recombinant proteins. 
 
We also tested the specific binding of recombinant CpACBP1-S to palmitoyl-CoA in 
comparison with that of full-length CpACBP1 using the same Lipidex assay. Under the 
condition of using 0.4 mM of protein and 0.8 mM of palmitoyl-CoA, both fusion proteins 
displayed similar specific binding activities (i.e., 0.180 and 0.206 pmol pmol-1 protein for 
CpACBP1 and CpACBP1-S, respectively), thus confirming that the ACBP domain was 
responsible for the acyl-CoA binding. 
 
The specific binding of CpACBP1 to fatty acyl-CoAs was further confirmed by 
autoradiography. When [14C] palmitoyl-CoA was incubated with various fusion proteins, 
only recombinant CpACPB1 (full-length) or CpACBP1-S (ACBP domain only), but not 
MBP-tag, displays radioactivity (Fig. 3.6). The radioactive intensity associated with the 
fractionated CpACBP1 was reduced when an equal molar amount of non-radioactive 
fatty acyl-CoA was added into the reaction. It is also noticeable that multiple radioactive 
bands were observed in lanes containing CpACBP1. Since protein fractionation was 
performed in native PAGE gels, this observation suggests that CpACBP1 may also 
function as dimers or tetramers. However, it is also possible that protein aggregation 
might occur under the experimental conditions used. 
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Fig. 3.6. Autoradiography showing the binding of [14C]-palmitoyl-CoA by full-length 
(lanes 1 and 2) and short ACBP-domain only (lanes 3 and 4) fusion proteins after native 
PAGE fractionation. MBP-tag only (lanes 5 and 6) was used as a control. In lanes 1, 3 
and 5, the same molar amount of non-radioactive palmitoyl-CoA was also included to 
compete with the radioactive acyl-CoA, which resulted in the reduced intensity of 
radioactivity in these lanes. Positions of CpACBP1 monomers, dimers and polymers are 
indicated. Some acyl-CoA molecules were retained in the loading wells as indicated. 
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Based on the specific binding data, we decided to test the substrate preference for 
CpACBP1 using 0.8 mM of various fatty acyl-CoAs to compete with the same molar 
concentration of palmitoyl-CoA. This concentration is ~ 2X of the Kd value for palmitoyl-
CoA, so that the protein occupancy by the ligands was neither too low or too high. The 
results show that CpACBP1 can bind to the medium and long chain acyl-CoAs (Fig. 
3.7).  
 
CpACBP1 gene is differentially expressed and its encoded protein is likely 
localized to the parasitophorous vacuole membranes (PVM) 
 
Semi-quantitative RT-PCR  showed that the CpACBP1 gene is expressed differentially 
in the complex parasite life cycle (Fig. 3.8). CpACBP1 transcripts were barely 
detectable in free sporozoites, but started to appear after parasites’ invasion into host 
cells. The level of CpACBP1 transcripts was relatively low during early intracellular 
development (i.e., from 3 to 24 hr post-infection, P.I.), but gradually increased with the 
time of infection (Fig. 3.9). 
  
More surprisingly, immunofluorescence microscopy indicates that CpACBP1 is probably 
located on the PVM (Fig. 3.10A,B,C). Rabbit polyclonal antibodies clearly labeled the 
surface of meronts with a homogeneous pattern of distribution, but failed to label the 
merozoites within the meronts (Fig. 3.10A). In a dual-labeling experiment using a rabbit 
polyclonal antibody mainly against PVM( the total membrane proteins’ antibody was 
made by our lab, which is localized on the membrane on the parasite) and the electron 
dense connection between host cell and parasite, we co-localized CpACBP1 and PVM 
proteins (Fig. 3.10B). On the other hand, a polyclonal antibody against CpSFP-PPT  
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Fig. 3.7. Acyl-CoA binding specificity of CpACBP1 determined by Lipidex 1000 
competition binding assay. In each reaction, [14C]-palmitoyl-CoA was mixed with the 
same molar amount of non-radioactive acyl-CoA with specified carbon chain length. 
The binding affinity was presented as the percent displacement of radioactive palmitoyl-
CoA by non-radioactive acyl-CoA. SEM values were determined from at least three 
individual samples. 
 36
 
 
Fig. 3.8. Relative levels of CpACBP1 gene transcripts in various Cryptosporidium 
parvum life cycle stages as determined by semi-quantitative RT-PCR. The level of 
transcripts is normalized using that of the parasite 18S rRNA as a control. Spz = 
excysted free sporozoites. 
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Fig. 3.9. Western blot detection of CpACBP1 protein in Cryptosporidium parvum 
oocysts, excysted free sporozoites, and intracellular parasites grown for 24 and 48 hr. 
CpACBP1 was only detected in the intracellular parasites, but not in oocysts and free 
sporozoites. 
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Fig. 3.10A. Indirect immuno-labeling of intracellular Cryptosporidium parvum grown for 
24, 48 and 72 hr using a rabbit polyclonal antibody against CpACBP1 and a secondary 
antibody conjugated with FITC.  
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Fig. 3.10B. Direct dual-labeling of intracellular parasites grown for 24 hr using an Alexa 
Fluor 546-conjugated antibody against CpACBP1 and an Alexa Fluor 488-conjugated 
antibody against parasite total membrane protein (TMP) that mainly labels 
parasitophorous vacuole membrane and feeder organ. Both antibodies displayed the 
same labeling pattern on the surface of a meront. 
 
 
 
Fig. 3.10C. Dual-labeling of intracellular parasites grown for 48 hr using an Alexa Fluor 
488-conjugated antibody against CpACBP1 and an Alexa Fluor 546-conjugated 
antibody against cytosolic CpSFP-PPT, showing CpACBP1 mainly on the surface of 
meronts, rather than in merozoites. DIC = differential interference contrast. DAPI = 4',6-
diamidino-2-phenylindole for counterstaining nuclei. Bar = 5 mm. 
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clearly labeled the merozoites, but not on the surface of meronts in another dual-
labeling experiment (Fig. 3.10C).  
 
DISCUSSION 
 
ACBP was originally identified as a mammalian diazepam binding inhibitor – a 
neuropeptide that could inhibit diazepam binding to the γ-aminobutyric acid (GABA) 
receptor (Guidotti et al., 1983). Typical ACBPs are small, ~10 kDa cytosolic proteins 
(Burton et al., 2005). However, there are a number of long-type ACBPs that are fused 
with ankyrin repeats, such as the ACBP1 and ACBP2 in Arabidopsis thaliana (Chye et 
al., 1999; Li & Chye, 2003), or with other functional domains, such as the human 
peroxisomal D3, D2-enoyl-CoA isomerase (Geisbrecht et al., 1999). ACBP mainly 
functions as an intracellular acyl-CoA transporter and pool former, and is critical to lipid 
metabolism in cells (Gossett et al., 1996; Knudsen et al., 2000; Schroeder et al., 1998). 
However, ACBP has only been found in eukaryotes, but not in prokaryotes except for a 
few pathogenic eubacteria that might have acquired ACBP from eukaryotic hosts via 
lateral gene transfer (Burton et al., 2005). 
 
Among apicomplexans, C. parvum only possesses a single, long-type ACBP that is 
fused with an ankyrin repeats domain. However, other apicomplexans may have 
multiple ACBP proteins of various types (i.e., short-type, long-types fused with ankyrin 
repeats or with uncharacterized sequences) (Fig. 3.1), indicating that the ACBP-
mediated metabolic pathways may be highly divergent in the Apicomplexa. Arabidopsis 
ACBP1 and ACBP2 are membrane proteins that differ from typical cytosolic ACBPs 
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(Chye et al., 1999; Leung et al., 2005). The ankyrin repeats in these proteins are 
responsible for docking these proteins to the membrane by interacting with an ethylene-
responsive element-binding protein. Our immuno-labeling data indicate that CpACBP1 
is also a membrane protein (i.e., mainly associated with PVM) (Fig. 3.10). Such a 
membrane association is likely mediated by the interaction of ankyrin repeats with a yet 
unknown protein(s) in the PVM.  
 
Although C. parvum is an intracellular parasite, it does not reside within the host 
cytoplasm. Instead, this parasite is extracytoplasmic, covered by PVM on the surface of 
intestinal epithelial cells (Chen et al., 2002b). Therefore, the PVM is the only barrier 
separating parasites from the intestinal lumen. The localization of CpACBP1 to the PVM 
is thus intriguing, although it is currently uncertain whether CpACBP1 is also associated 
with the feeder organ at the host cell-parasite interface. It implies that CpACBP1 may 
be involved in the formation of the PVM or uptake of fatty acids across the PVM. 
However, since CpACBP1 mRNA and protein are undetectable (or barely detectable) in 
sporozoites and in the invasion stages (i.e., first 3 hr of infection), it seems less likely 
that CpACBP1 is associated with the early stage of PVM formation. On the other hand, 
it is known that C. parvum may have to import fatty acids from host cells or the intestinal 
lumen since it is likely to be incapable of synthesizing fatty acids de novo, although it is 
capable of elongating long chain fatty acids (Zhu, 2004b). Therefore, it is possible that 
CpACBP1 may function as a fatty acyl-CoA scavenger in conjunction with an acyl-CoA 
synthetase on or around the PVM (or the feeder organ) to facilitate the fatty acid uptake 
by the parasite.  
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Another possibility is that CpACBP1 may be involved in the synthesis of a glycosyl-
phosphatidylinositol (GPI) anchor. In African trypanosomes, ACBP has been found to 
be responsible for supplying myristoyl-CoA to the fatty acid remodeling machinery 
during GPI synthesis (Milne & Ferguson, 2000; Milne et al., 2001). Although it is yet 
unclear whether GPI anchored molecules are present in the PVM, a recent 
comprehensive chemical analysis has clearly revealed the presence of complex 
glycosylinositol phospholipids in the C. parvum sporozoites (Priest et al., 2003). In 
addition, a number of enzymes involved in the biosynthesis of GPI anchors are also 
present in the C. parvum genome, which includes phosphatidylinositol N-
acetylglucosaminyltransferases (e.g., Genbank accession numbers XP_628152, 
XP_627129 and XP_626317). Nonetheless, further investigations are necessary to test 
these hypotheses. 
 
CpACBP1 has highest affinity for palmitoyl-CoA (C16:0) with a gradually decreased 
binding affinity for other acyl-CoA esters. However, CpACBP1 is incapable of binding 
CoA esters with an acyl chain of 20 carbons or longer. This feature makes CpACBP1 
different from many other ACBP proteins, including those from bovines and 
trypanosomes that can bind to CoA esters with an acyl chain of 24 or more carbons 
(Milne & Ferguson, 2000; van Aalten et al., 2001).  
 
The expression pattern of CpACBP1 differs from that of many other C. parvum genes, 
such as the replication protein A (RPA) subunits, CpSFP-PPT and b-tubulin, but is 
similar to those of oocyst wall proteins in this parasite (Abrahamsen & Schroeder, 1999; 
Cai et al., 2005; Millership et al., 2004a; Rider et al., 2005). Such a differential 
expression pattern is also supported by western blot and immunofluorescence 
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microscopic analyses that only detected CpACBP1 protein in the intracellular parasites, 
but not in oocysts or free sporozoites (Figs. 3.9 and 3.10A,B,C). 
 
Our biochemical data show that, although CpACBP1 can bind to medium to long chain 
fatty acids with chain lengths up to 18-carbons, it displays highest binding affinity 
towards to the C16:0 palmitoyl-CoA. The Kd value at 407 nM was obtained by Lipid 
1000 assay, which is comparable to those of other ACBPs determined by the same 
assay (Rasmussen et al., 1994). However, this value does not represent the true acyl-
CoA binding affinity. Rather, it reflects the competitive binding between ACBP and 
Lipidex 1000 (Rasmussen et al., 1994). The Kd values determined by fluorescence or 
dialyzer-based methods are typically at lower nM range (i.e., 1 – 10 nM) (Chao et al., 
2002; Frolov & Schroeder, 1998; Milne & Ferguson, 2000; van Aalten et al., 2001; 
Wadum et al., 2002). On the other hand, although Lipidex 1000 cannot be used to 
assess the true binding affinity for ACBPs, this method can be used as a qualitative 
assessment, such as the ligand competition assay. Autoradiography indicates that both 
the full-length CpACBP1 protein and its ACBP domain may form dimers or even 
polymers (Fig. 3.5). However, it is unclear whether CpACBP1 is truly present as dimers 
or polymers in the parasites, or the observed multiple bands in autoradiography are 
only an artifact induced by the experimental conditions. 
 
Fatty acids are essential to all organisms. Recently, fatty acid metabolism has been 
considered as a promising target for the drug development against cryptosporidiosis 
and other important apicomplexans (Gornicki, 2003; Kuo et al., 2003; Ralph et al., 2001; 
Roberts et al., 2003; Waller et al., 2003; Zhu, 2004b). Because ACBP plays a critical 
role in fatty acid metabolism, it is reasonable to speculate that CpACBP1 and other 
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apicomplexan ACBPs may be explored as new drug targets for the control of 
cryptosporidiosis or other apicomplexan-based diseases. This notion is further 
supported by the targeted disruption of ACBP in tryponosoma brucei causing the 
lethality (Milne et al., 2001). A more detailed investigation on the structure of parasites’ 
ACBPs may contribute to possible therapeutic targets. 
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CHAPTER IV 
 
TWO DISTINCT OXYSTEROL BINDING PROTEIN-RELATED PROTEINS  
FROM APICOMPLEXAN  CRYPTOSPORIDIUM PARVUM * 
 
INTRODUCTION 
 
Cryptosporidium parvum is a parasitic protist belonging to the Phylum Apicomplexa, in 
which all members are parasites and many of them are important pathogens in humans 
and/or animals (e.g., Plasmodium, Babesia, Toxoplasma, Cyclospora, and Eimeria) 
(Thompson et al., 2005; Tzipori & Widmer, 2000a; Zhu et al., 2000a). This parasite 
infects both humans and animals, causing various degrees of watery diarrhea that is 
typically self-limited in immunocompetent individuals, but prolonged and life-threatening 
in immunocompromised patients (Chappell & Okhuysen, 2002; Chen et al., 2002b). 
Unlike other apicomplexan parasites, C. parvum parasitizes on the surface of epithelial 
cells, rather than within the host cell cytosol. However, it is also covered by a layer of 
parasitophorous vacuole membrane (PVM) that is mostly derived from host cell 
membranes, which makes C. parvum an intracellular, but extracytoplasmic parasite 
(Chen et al., 2002b; Tzipori & Widmer, 2000a). 
 
In comparison to other apicomplexans, C. parvum apparently has the most streamlined  
 
 
 
 
*Reprinted with permission from “Two distinct oxysterol binding protein-related proteins 
in the parasitic protist Cryptosporidium parvum (Apicomplexa)” by Zeng, B. & Zhu, G., 
2006. Biochem Biophys Res Commun 346, 591-99. Copyright 2006 by Elsevier. 
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and simplified metabolism encoded by its genome (Abrahamsen et al., 2004). It differs 
from other apicomplexans in a number of key metabolic pathways. For example, this 
protist lacks an apicoplast and associated metabolic pathways including the Type II 
fatty acid synthase (FAS), but uses a multifunctional Type I FAS (CpFAS1), a Type I 
polyketide synthase (CpPKS1), and a long chain fatty acid elongase (CpLCE1)-
mediated pathway for elongating fatty acids (Abrahamsen et al., 2004; Zhu et al., 
2000e; Zhu et al., 2002; Zhu, 2004b; Zhu et al., 2004b). Cryptosporidium also lacks 
most (if not all) de novo synthetic pathways, thus likely relying solely on the update of 
nutrients (such as lipids, sugars, amino acids and nucleosides) from host cells or the 
intestinal lumen. Genes encoding sugar, amino acid and nucleoside transporters have 
been identified from the C. parvum genome, some of which are being characterized 
(Abrahamsen et al., 2004). However, typical fatty acid transporters are absent in the 
parasite, and it is yet unclear how this parasite uptakes fatty acids and lipids from the 
host environment. Recently, we have characterized a unique, long-type acyl-CoA 
binding protein from C. parvum (CpACBP1) that is capable of binding long chain fatty 
acyl-CoA esters (Zeng et al., 2006a). CpACBP1 has been chiefly localized to the PVM, 
implying that this membrane protein is involved in the import of activated fatty acids 
from the intestinal lumens, or lipid remodeling within the PVM, or both. Since CpACBP1 
is undetectable in the invasive sporozoites and in the entry stage during the parasite 
intracellular development, this protein is less likely essential to the formation of PVM. 
These observations indicate that the PVM may play an important role in nutrient uptake 
by the parasite. 
 
In the present study, we report the identification and preliminary characterization of two 
oxysterol binding protein (OSBP)-related proteins (ORPs) from C. parvum (CpORP1 
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and CpORP2). OSBPs and ORPs have been found to be involved in the transport and 
metabolism of cholesterol and related lipids in eukaryotes (Beh & Rine, 2004; Hynynen 
et al., 2005; Im et al., 2005; Lehto & Olkkonen, 2003; Olkkonen, 2004; Olkkonen & 
Levine, 2004; Perry & Ridgway, 2005; Wang et al., 2005a; Wang et al., 2005b; Wang et 
al., 2005c). Although OBSP was originally identified from humans by its capacity to bind 
to oxysterols, not all ORPs share the same binding capacity. However, all OSBPs and 
ORPs have been found to be able to bind to different phosphatydinositol phosphates 
(PIPs) with various affinities (Lehto & Olkkonen, 2003; Olkkonen, 2004). Here we have 
expressed both CpORP1 and CpORP2 as recombinant proteins and determined their 
substrate-binding profiles towards various PIPs. We have also localized one of the 
parasite proteins (CpORP1) to the PVM, suggesting that this protein may be involved in 
the lipid-trafficking and/or remodeling within the PVM. 
 
METHODS 
 
Identification of ORPs from C. parvum and other apicomplexans 
 
By data-mining the newly sequenced C. parvum genome, our laboratory has identified 
two genes that encode ORP homologues. Both gene products have been annotated by 
the C. parvum genome consortium as “oxysterol binding protein” (Genbank accession 
No. XP_627892) and “oxysterol binding protein 1A-like pleckstrin homology (PH) 
domain containing protein” (EAK87842). For clarification, we have named these two 
proteins as CpORP1 and CpORP2, and their genes as CpORP1 and CpORP2. 
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Similarly, two ORP homologues were also identified from the C. hominis genome that 
were referred to as ChORP1 and ChORP2. 
 
We also data-mined the completely (or near completely) sequenced genomes from 
other distinct groups of apicomplexans, i.e., Plasmodium falciparum, P. vivax and P. 
yoelii at http://PlasmoDB.org (release 4.4), Toxoplasma gondii at http://ToxoDB.org 
(release 3.0), as well as Eimeria tenella at http://www.sanger.ac.uk/Projects/E_tenella 
(assembled contigs from 8X coverage of the whole genome, last access on May 10, 
2006). Among them, the two C. parvum ORPs proteins were used as queries to BLAST 
searches against the genome and predicted proteins (available for at PlasmoDB and 
ToxoDB). The resulting hits were retrieved and subjected to further analysis, including 
homology searches and identification of domains to confirm their identity as members of 
the ORP family. 
 
Molecular cloning and engineering of CpORP1 and CpORP2 gene 
 
To confirm the function of these apicomplexan ORP homologues, we engineered and 
expressed the two C. parvum ORPs for ligand binding studies. Both CpORP1 and 
CpORP2 are intronless genes, which permits the amplification of their entire open 
reading frames (ORFs) directly from genomic DNA (gDNA isolated from the same the 
source and DNA extraction method as the chapter III). PCR amplification employed a 
mixture of Pfu and Taq DNA polymerases (1 unit each per 50 ml reaction) and the 
following two primer pairs: CpORP1-F1 (5’- gcg gatc cAT AAT AGT GTG GAG GTA 
AAT CAT ATG -3’) and CpORP1-R1 (5’- gcg gat ccT TAT TTA TCG ATA TTA AAA 
ATA TCA AT -3’); CpORP2-F1 (5’- gcg gat ccA TGT TGG TTA ATG AGC AAT CAA 
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AAA AA -3) and CpORP2-R1 (5’- gcg gat ccT CAA AAA ATA TTT GGT AAA TCT GTA 
AA -3)’ (Note: lower cases represent added BamHI restriction site). The PCR amplicons 
were first cloned into pCR4Blunt-TOPO vector with the use of TOPO cloning kit 
(Invitrogen). After sequencing to confirm the identity, the CpORF1 and CpORF2 inserts 
were released by BamHI restriction digestion and ligated into linearized pMAL-c2x 
vector (New England Biolabs). The resulting plasmids were again sequenced to confirm 
the identity and orientation of the inserts, and the correct clones were used for 
expression of maltose-binding protein (MBP)-fusion proteins. The Rosetta strain of 
Escherichia coli (Novagen) containing extra set of tRNA for correcting the codon use 
bias between bacterial and eukaryotic genes was used to host the expression of the 
fusion proteins. 
 
The entire expression procedure started with the inoculation of a single colony of 
bacterial transformants into 10 ml LB broth containing 100 mg/ml ampicillin and 34 
mg/ml chloramphenicol, which was allowed to grow at 37 °C overnight. The bacterial 
suspension was then mixed into 1 L fresh broth containing the two antibiotics. After 
incubation at room temperature until the OD495 reached to 0.3-0.5, IPTG was added into 
the broth at a final concentration of 0.1 mM, followed by an 8-hr expression at 16 °C. 
The bacteria were centrifuged at 8000 g for 10 min at 4 °C, and the pellet was 
suspended in 50 ml of column buffer (20 mM Tris-HCl, 20 mM NaCl, 2 mM EDTA, pH 
7.5) with a protease inhibitor cocktail formulated for bacteria (Sigma-Aldrich). Bacterial 
cells were ruptured by a mild sonication on ice and cell debris was removed by 
centrifugation at 8,000 g for 10 min. The supernatant was loaded to an amylose-resin 
column (New England Biolabs). After washing with more than 10 volumes of column 
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buffer, the MBP-fused proteins (MBP-CpORP1 and MBP-CpORP2) were eluted by an 
elution buffer (i.e., column buffer containing 10 mM maltose). Ten percent SDS-PAGE 
was used to analyze the size and purity of fusion proteins. The Bradford method was 
used to determine the protein concentrations (ref). Aliquots of each protein were either 
used immediately or stored at -80 °C for future use. 
 
Lipid-protein overlay assay 
 
The nitrocellulose membrane blots spotted with various phosphoinositides (PIP strips) 
and sphingolipids (SphingoStrips) were purchased from Molecular Probes. To 
determine the binding specificity of recombinant CpORP1 and CpORP2 with 
phosphoinositides and sphingolipids, membrane blots were first treated with a blocking 
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween 20, 2 mg/ml fatty acid-free 
bovine serum albumin [BSA]) for 1 hr. The blots were then incubated overnight at 4°C 
with gentle rotation in a fresh blocking buffer containing 5 nM of the MBP-fusion 
proteins and washed for 10 times (5 min each) in a TBST buffer (50 mM Tris-HCl, pH 
7.5, 150 mM NaCl, 0.1% Tween-20). The detection of bound proteins was facilitated by 
a typical Western blot analysis procedure. Briefly, the blots were incubated with a rabbit 
anti-MBP polyclonal antibody (New England Biolabs) in blocking buffer for 1 hr, washed 
with TBST for 6 times (5 min each) to remove free antibodies, incubated with an 
alkaline phosphatase (AP)-conjugated goat anti-rabbit IgG secondary antibody (Sigma-
Alderich) in TBST for 1 hr, and washed again with TBST for 12 times (5 min each). The 
proteins were then visualized using 5’ bromo-4-chloro-3-indolyl phosphate (BCIP)/nitro 
blue tetrazolium (NBT) (substrate source) as substrates for AP. In all experiments, 
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separate PIP strips and SphingoStrips were also incubated with MBP-tag alone as 
controls. 
 
Production of rabbit polyclonal antibodies to CpORP1  
 
The antigen used in antibody production was a stretch of MBP-fused short peptide 
(134LNTTK TCVEN EDIEK EETCN ITRRR NLPVP KTSAK FSLLS MMRQV FGKDL 
SRISM188) in CpORP1. This sequence is unique to CpORP1 and reasonably antigenic 
as determined by various antigenicity indexes using MacVector v.8.1.1 program. The 
engineering, expression and purification of fusion proteins followed similar procedure as 
described above for the full-length CpORP1 and CpORP2 proteins. Polyclonal 
antibodies to the recombinant CpORP1 antigen were raised in two pathogen-free 
rabbits in a commercial site (Lampire Biological Laboratories, Pipersville, PA). Rabbit 
preimmune sera were pre-screened by dot blot test using parasite oocyst protein 
extracts, and only the rabbits with no reactive sera were used for antibody production. 
The following immunization protocol was used. On day 1, preimmune rabbit sera were 
collected and initial immunization was performed using 0.2 mg of antigen emulsified 
with 0.5 ml of complete Freund’s adjuvant. Two booster shots (0.1 mg of antigen each) 
with 0.5 ml of incomplete adjuvant were performed on day 21 and day 42. Rabbit 
antisera were collected on day 50. The titers and specificity of the rabbit polyclonal 
antibodies were evaluated by dot and western blot analysis with recombinant proteins 
and protein extracts of parasites and host cells. 
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Immunofluorescence microscopy for detecting CpORP1 during the parasite 
development 
 
The expression and localization of CpORP1 in the invasive stage (sporozoites) and 
intracellular parasites were studied by immuno-labeling. Free C. parvum sporozoites 
(IOWA strain) were prepared by incubating oocysts in an excystation medium 
containing 0.25% trypsin and 0.5% TDC in PBS (pH 7.2) for 90 min at 37 C. Excystation 
was stopped by adding an equal volume of 20% BSA (chilled on ice) into the medium, 
followed by washes with PBS for 5 times by centrifugation. Intracellular parasites were 
prepared by infecting HCT-8 cells with C. parvum for various time periods. Host cells 
were seeded on poly-L-lysine-treated glass coverslips and grown for 24 hr. Parasite 
oocysts were sterilized by a 10-min treatment with 10% Clorox on ice, washed 8 times 
with distilled water by centrifugation, resuspended in culture medium, and added to the 
24-well plates containing cultured cells in a ratio of 1 oocyst per 5 host cells. Parasite 
excystation and invasion into host cells was allowed to take place for 3 hr at 37 °C. 
Parasites that failed in excystation and invasion were removed from the culture by a 
medium exchange. Infected cells were then allowed to grow for 12, 24, 48 and 72 hr, 
and fixed in 10% formalin solution balanced with PBS. Fixed cells were rinsed with PBS 
and water respectively, and extracted with methanol/acetone (v/v = 1:1) for 5 min at –20 
°C. Samples were rinsed with water and then PBS, blocked in 0.5 % BSA in PBS (BSA-
PBS) for 10 minutes, labeled with 1:500 dilution primary antibodies in PBS containing 
0.5 % BSA for 1 h, and treated with a TRITC-conjugated monoclonal antibody against 
rabbit IgG (Sigma-Aldrich ,1/400 dilution). Samples were washed with PBS containing 
0.05% Tween-20 for 3 times after each incubation step. Slides were mounted by a 
SlowFade Light Antifade mounting medium (Molecular Probes) containing 4’,6’-
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diamidino-2-phenylindole (DAPI) for counterstaining nuclei and examined using an 
Olympus BX51 Epi-Fluorescence microscope system equipped with differential 
interference contrast (DIC) apparatus and FITC/TRITC/DAPI filters. 
 
RESULTS   
 
Sequence characterization of ORPs in Cryptosporidium and other apicomplexans 
 
OSBP and ORPs are a family of proteins only found in eukaryotes (Lehto & Olkkonen, 
2003). Indeed, extensive BLAST searches using ORPs from animals, plants, yeast and 
protists failed to identify any significant homologues from the other two domains of life 
(i.e. eubacteria and archaea). Although ORPs have been found to be critical in the lipid 
metabolism, most recent investigations have mainly focused on human and yeast 
homologues (Lehto & Olkkonen, 2003). No ORPs were previously reported or 
characterized from protists – the most divergent group of unicellular organisms. 
Therefore, the apicomplexan ORPs reported here represent the first ones characterized 
from protists. 
 
The C. parvum genome contains two ORPs, which differs significantly from human host 
that possess at least 12 ORPs, as well as from yeast that has 7 ORP homologues 
(Jaworski et al., 2001; Lehto & Olkkonen, 2003). Sequence analysis clearly separated 
these two CpORPs into two distinct categories: the 70-kDa CpORP1 belongs to the 
short-type family that contains only a ligand binding (LB) domain, while the 90-kDa 
CpORP2 is a long-type protein that contains an N-terminal Pleckstrin homology (PH) 
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domain and a C-terminal LB domain (Fig. 4.1). Both ORPs possess the highly 
conserved “fingerprint” sequence found in all human and yeast ORPs (i.e., 
EQVSHHPP) with only one amino acid difference (i.e., the Ser residue is replaced by 
Met in CpORP1 and by Gly in CpORP2) (Fig. 4.1, indicated by ovals within the LB 
domains) (Lehto & Olkkonen, 2003). However, CpORP1 and CpORP2 appear more 
divergent from each other than expected, as these two proteins only share ~20% 
identity at the amino acid level. This suggests a possible very early split between these 
two proteins, probably before the separation of the Cryptosporidium lineage from other 
apicomplexans.  
 
In addition, both types of ORPs are also present in the genome of C. hominis (ChORP1 
and ChORP2), a species that is mostly found to infect humans and was previously 
known as the Type 1 genotype of C. parvum. These two Cryptosporidium species 
virtually share identical amino acid sequences for the two ORPs. There are only 8 
amino acid substitutions between CpORP1 and ChORP1 (1.4%), and 13 between 
CpORP2 and ChORP2 (1.6%), respectively. 
 
More surprisingly, other apicomplexans (including the three Plasmodium species, T. 
gondii, and E. tenella) possess only a single ORP homologue in each of their genomes. 
The predicted protein sequences for Plasmodium and Toxoplasma ORPs were 
available in their corresponding databases (Fig. 4.1), while only the genomic contig 
containing the ORP homologue was available for E. tenella.  
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Fig. 4.1. Domain organization of ORPs from Cryptosporidium parvum (CpORP1 and 
CpORP2) and other two apicomplexans, Toxoplasma gondii (TgGLEAN_1667) and 
Plasmodium falciparum (Pf11_0327). PH and LB represent Pleckstrin homology domain 
and ligand binding domain, respectively. Oval circles indicate ORP “fingerprint” 
sequences within the LB domains. Gray region within the P. falciparum protein indicates 
a stretch of inserted amino acids within the LB domain. Asterisks indicate sequences 
that were retrieved from corresponding genome databases (i.e., http://ToxoDB.org and 
http://PlasmoDB.org).  
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Ligand binding property of CpORP1 and CpORP2 
 
Both CpORP1 and CpORP2 were successfully expressed as MBP-fusion proteins at 
expected sizes and purified to homogeneity using amylose-based affinity 
chromatography (Fig. 4.2). The expression levels of these fusion proteins were 
generally low (i.e., < 1 mg/L), but sufficient protein could be purified from several liters 
of culture for biochemical analysis.  
 
Lipid-protein overlay assays using PIP strips clearly showed that CpORP1 and 
CpORP2 could bind to phosphatidic acid (PA) and various phosphatidylinositol 
phosphates (PIPs) (Fig. 4.3A). Both fusion proteins displayed almost identical binding 
patterns, despite their sequence divergence, and showed the highest binding affinity to 
PA, the three phosphatidylinositol mono-phosphates [i.e., PI(3)P, PI(4)P, and PI(5)P], 
and slightly reduced affinities to phosphatidylinositol bi- and tri-phosphates [i.e., 
PI(3,4)P2, PI(3,5)P2, PI(4,5)P2 and PI(3,4,5)P3]. Both proteins displayed little or no 
affinity to other phospholipids included in the same blots, including phosphatidylserine 
(PS), sphingosine 1-phosphate [Sp(1)P], phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylinositol (PIP), lysophosphatidylcholine 
(LPC), and lysophosphatidic acid (LPA) (Fig. 4.3B and Fig. 4.3C). The binding between 
MBP-fused proteins and PA/PIPs was specifically contributed by the parasite ORP 
portion, since the MBP-tag alone displayed no affinity at all towards to any of the lipids 
on the membranes (Fig. 4.3B and Fig. 4.3C). 
 
In another lipid-protein overlay assay using SphingoStrips, CpORP1 and CpORP2 
showed no affinity to any of the lipids with small head groups, but only strongly bound to  
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Fig. 4.2. SDS-PAGE analysis of affinity chromatography purified maltose-binding 
protein (MBP) fused CpORP1 and CpORP2 proteins. Lane 1 = MBP-CpORP1; Lane 2 
= blank; Lane 3 = MBP-CpORP2; M = Protein molecular weight markers. 
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Fig. 4.3A. Binding affinity of CpORP1 and CpORP2 towards various 
phosphatidylinositol phosphates (PIPs) as determined by measuring the signal 
intensities (integrated densities) generated in lipid-protein overlay assay using ImageJ 
v1.3.7 program (available at http://rsb.info.nih.gov/ij/). Bars represent SEM values from 
three PIP membrane blots.  
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Fig. 4.3B. Representative membrane blots (PIP strips and Sphingo Strips) resulting 
from lipid-protein overlay assay using recombinant CpORP1 and CpORP2 proteins. 
MBP-tag alone was used as controls.  
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Fig. 4.3C. Legends for the PIPs and sphinogolipids spotted on the blots. Preferred 
ligands are shown in bold.  
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sulfatide, a 3-sulfate ester of galactosylcerebrosides (Fig. 4.3B). In addition, both 
proteins showed no binding affinity to cholesterol that was found to be a ligand for some 
ORPs (such as human OSBP and yeast Osh4 (Im et al., 2005), which suggests that 
both parasite ORPs are unlikely (or at least not directly) to be involved in cholesterol-
sensing in the parasite. 
 
Localization of CpORP1 in intracellular parasites 
 
To facilitate the study of localization of CpORPs, we developed a rabbit polyclonal 
antibody to CpORP1 by immunizing rabbits with a recombinant protein containing 55 
amino acids unique to CpORP1. The production of antibodies to CpORP2 is currently 
ongoing, as our initial attempts to raise antibodies to CpORP2 were unsuccessful. 
Using the mono-specific polyclonal antibody, we first found that CpORP1 was not 
present (or present at an undetectable level) in the environmental stages including 
intact oocysts and the excysted invasive sporozoites, both by western blot analysis and 
by immunofluorescence microscopy (data not shown). However, CpORP1 proteins 
could be clearly detected among intracellular parasites developed for various times 
(Fig. 4.4A). In general, the fluorescence signal resulting from the immuno-labeling 
covered homogenously the entire surface of meronts (both 1st and 2nd generations of 
meronts) with more intensive signals along the edges. These features of labeling are 
typical to proteins present on the PVM – a host cell membrane-derived barrier between 
parasites and the intestinal lumen (Chen et al., 2003; Zeng et al., 2006a; Zeng et al., 
2006b), although one can not completely rule out the possibility of some minor 
distribution of CpORP1 in the merozoites and/or the electron-dense feeder organelle 
connecting parasites and host cells. 
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Fig. 4.4A. Immunofluorescence microscopic detection of CpOPR1 proteins in 
intracellular Cryptosporidium parvum cultured in vitro for 12, 24, 48 and 72 hr, 
respectively. DIC =  differential interference contrast. DAPI = 4’,6’-diamidino-2-
phenylindole for counterstaining nuclei. TRITC = labeled CpORP1 proteins. Merge = 
DAPI-stained nuclei + TRITC-stained CpORP1. Note: In some DAPI stained slides, 
host cell nuclei were also stained and shown as large blue backgrounds. Bar = 5 mm. 
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 Fig. 4.4B. Diagram of a parasite meronts containing 8 merozoites. Parasitophorous 
vacuole membrane (PVM) labeled by anti-CpORP1 antibody is shown in red. N = 
nucleus.  
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DISCUSSION 
 
In contrast to CpORP1 and CpORP2 that are intronless, all other apicomplexan ORP 
genes are heavily interrupted by introns and encode the long-type ORPs containing an 
N-terminal PH domain. These ORPs are generally much larger than their counterpart in 
C. parvum (CpORP2) by containing extra amino acids between the PH and LB 
domains. The ORPs from various Plasmodium species also containing in large insertion 
within the LB domain, shortly after the “fingerprint” sequence (Fig. 4.1, marked in gray). 
There is also a single amino acid substitution at the “fingerprint” sequence, in which the 
Ser is replaced by Gly in T. gondii and by Val in P. falciparum, respectively. These 
observations suggest that the function of PH domain-containing ORPs may be shared 
among all apicomplexans, but that of short CpORP1 is probably unique to 
Cryptosporidium. 
 
Low temperature expression at 16 °C could enhance the expression level and the 
amount of soluble protein. Fresh bacterial transformants (< 1 week old) generally 
performed much better than older ones. The use of Rosetta strain of bacteria was also 
critical to expression of the AT-rich genes from C. parvum. 
 
Similar patterns of CpORP1 present on the PVM were recently reported for an acyl-CoA 
binding protein (CpACBP1) that binds to various long chain fatty acyl-CoAs (Zeng et al., 
2006a). Because C. parvum lacks apparent de novo synthetic pathways for fatty acids 
and sterols, and likely has to uptake these nutrients from either host cells or the 
nutrient-rich intestinal lumens (Zhu, 2004b), it has been speculated that CpACBP1 may 
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be involved in the transport of activated fatty acids across the PVM and/or the lipid 
remodeling within the PVM. The involvement of ORPs in intracellular lipid metabolism 
and trafficking has been well documented in yeast and human cells (Hynynen et al., 
2005; Im et al., 2005; Lehto & Olkkonen, 2003; Olkkonen, 2004; Perry & Ridgway, 
2005). It is reasonable to assume that CpORP1 may also be involved in the transport 
and/or regulation of lipid, particularly sterols, across the PVM, although such a 
hypothesis remains to be tested in the future. 
 
On the other hand, although CpACBP1 and CpORP1 are likely critical to the parasite 
intracellular development, both proteins are not present in the intact oocysts and 
excysted free sporozoites, suggesting they may play little or no role in the parasite 
environmental (extracellular) stages, or that their functions are not essential (or 
important) for the parasite survival in the environment, for the excystation and 
movement of sporozoites in the gut, and for the early stage of invasion of parasites into 
host cells. 
 
Although CpORP1 has been chiefly localized to the PVM, the subcellular location of 
CpORP2 is yet undetermined. We are currently in a process to raise antibodies to 
CpORP2 and will report related findings in the future. Since the PH domain-containing 
ORPs are also present in other apicomplexans of divergent lineages, further studies on 
CpORP2 will potentially reveal some common features shared among all 
apicomplexans. 
 
In summary, we have identified, cloned and expressed two distinct ORPs from the 
parasitic protist C. parvum. This feature indicates Cryptosporidium differs from other 
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apicomplexans including the Haematozoa and the Coccidia that all possess only one 
PH domain containing ORP in their genomes. Using the recombinant proteins, we have 
performed the lipid-protein overlay assay and confirmed that CpORP1 and CpORP2 
could specifically bind to PA and various PIPs, a feature that is characteristic to this 
family of proteins. Immuno-staining has chiefly localized CpORP1 to the PVM, 
suggesting that this protein may be involved in the lipid transport across the membrane 
barrier between intracellular parasites and host intestinal lumen. If the two ORPs are 
essential to intracellular parasite development, it is possible to explore these PVM 
proteins as chemotherapeutic and/or immunotherapeutic targets in this parasite for 
which fully effective treatment is yet unavailable.  
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CHAPTER V 
 
SUMMARY AND CONCLUSIONS 
 
There are two major areas of research reported in this dissertation, which concern the 
unique long-type ACBP and two distinct ORP homologues in Cryptosporidium parvum, 
and can be summarized as follows. 
 
First, we have identified and conducted functional analysis of a fatty acyl-CoA binding 
protein (ACBP) gene from the opportunistic protist C. parvum. The CpACBP1 gene 
encodes a protein of 268 aa that is 3X larger than the typical ACBP proteins (i.e., ~90 
aa) of humans and animals. Sequence analysis indicated that CpACBP1 consists of an 
N-terminal ACBP domain (~ 90 aa) and a C-terminal ankyrin repeat sequence (~ 170 
aa). The entire CpACBP1 ORF was engineered into a maltose-binding protein fusion 
system and expressed as a recombinant protein for functional analysis. Acyl CoA-
binding assays clearly revealed that the preferred binding substrate for CpACBP1 was 
palmitoyl-CoA. RT-PCR, Western blotting and immuno-labeling analyses clearly 
showed that the CpACBP1 gene was mainly expressed in the intracellular 
developmental stages and the level increases during the parasite development. 
Immunofluorescence microscopy shows that CpACBP1 is associated with the 
parasitophorous vacuole membrane (PVM), which implies that this protein may be 
involved in the lipid remodeling in the PVM or the transport of fatty acids across the 
membrane. 
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Second, we have identified two distinct oxysterol binding protein (OSBP)–related 
proteins (ORPs) from the parasitic protist C. parvum (CpORP1 and CpORP2). The 
short-type CpOPR1 contains only a ligand binding (LB) domain, while the long-type 
CpORP2 contains Pleckstrin homology (PH) and LB domains. Lipid-protein overlay 
assays using recombinant proteins revealed that CpORP1 and CpORP2 could 
specifically bind to phosphatidic acid (PA), various phosphatidylinositol phosphates 
(PIPs), and sulfatide, but not to other types of lipids with simple heads. Cholesterol was 
not a ligand for these two proteins. CpOPR1 was found mainly on the parasitophorous 
vacuole membrane (PVM), suggesting that CpORP1 is probably involved in the lipid 
transport across this unique membrane barrier between parasites and host intestinal 
lumen. Although Cryptosporidium has two ORPs, other apicomplexans including 
Plasmodium, Toxoplasma and Eimeria possess only a single long-type ORP, 
suggesting that this family of proteins may play different roles among apicomplexans. 
 
It is intriguing that both CpACBP1 and CpORP1 proteins were found to be associated 
with the PVM, which clearly displays the importance of this unique membrane structure 
in the transport and/or metabolism of lipids in C. parvum. 
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